Join

Compare · PASG vs TSHA

PASG vs TSHA

Side-by-side comparison of Passage Bio Inc. (PASG) and Taysha Gene Therapies Inc. (TSHA): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PASG and TSHA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • TSHA is the larger of the two at $1.14B, about 97.1x PASG ($11.8M).
  • Over the past year, PASG is down 56.1% and TSHA is down 28.7% - TSHA leads by 27.5 points.
  • PASG has been more active in the news (5 items in the past 4 weeks vs 2 for TSHA).
  • TSHA has more recent analyst coverage (18 ratings vs 12 for PASG).
PerformancePASG-56.14%TSHA-23.01%
2025-10-16+0.00%2026-10-15
MetricPASGTSHA
Company
Passage Bio Inc.
Taysha Gene Therapies Inc.
Price
$3.66-19.21%
$3.63-2.68%
Market cap
$11.8M
$1.14B
1M return
-24.69%
-29.79%
1Y return
-56.14%
-28.68%
Sector
Health Care
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2020
2020
News (4w)
5
2
Recent ratings
12
18
PASG

Passage Bio Inc.

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (ß-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A, as well as programs for the treatment of adult CNS indication. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

TSHA

Taysha Gene Therapies Inc.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.

Latest PASG

Latest TSHA